Reply to article “Actualización práctica sobre la palmitoiletanolamida (peaum) oral en el manejo del dolor crónico. Revisión narrativa”

• David Briskey ^[1]
  1. [1] University of Queensland

     University of Queensland

     Australia

     
• Localización: MPJ Multidisciplinary Pain Journal, ISSN-e 2697-2263, Nº. 1, 2024
• Idioma: español
• Enlaces
  • Texto completo
• Resumen

  • The following is a reply to a recently published manuscript that in our view contains several incorrect references and misleading information. The manuscript has misrepresented data and misled readers with the content in relation to the evidence/references that it has provided to support statements made within the manuscript. In particular, the PEA formulation Levagen+ has been referenced as having inferior absorption. To date, no studies have been conducted comparing Levagen+ to other formulations and therefore this statement is currently unsupported by evidence.